retatrutide safety profile clinical trials Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Dosage Chart: Doses, Units

Clinical evidence: Researchers have shown that Mounjaro can significantly lower weight in people with obesity

As a result, food remains in the stomach longer, promoting an earlier and prolonged sensation of fullness after meals

The scale stops moving even at the maximum tirzepatide dose

They are particularly useful for people who: Have type 2 diabetes with excess weight Struggle with hypoglycaemia on other therapies Have established cardiovascular disease Want to delay or minimise insulin use Frequently Asked Questions What does GLP-1 stand for

Finally, it is worth mentioning that flatulence may occasionally appear, although studies reporting its frequency are lacking